iBio (IBIO) Net Income towards Common Stockholders (2010 - 2026)

iBio (IBIO) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$7.7 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 59.02% year-over-year to -$7.7 million in Q1 2026; TTM through Mar 2026 was -$27.5 million, a 54.88% decrease from a year earlier, with the FY2025 full-year figure at -$81.6 million, down 761.76% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$7.7 million, up from -$9.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for IBIO reached as high as -$537000.0 in Q1 2024 and fell as low as -$23.0 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$6.6 million across 5 years, with a median of -$4.9 million in 2025.
• Across the five-year window, Net Income towards Common Stockholders plunged 33539.22% in 2022 and jumped 93.54% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$23.0 million in 2022, then jumped by 83.81% to -$3.7 million in 2023, then dropped by 17.22% to -$4.4 million in 2024, then sank by 106.07% to -$9.0 million in 2025, then climbed by 14.04% to -$7.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$7.7 million in Q1 2026, -$9.0 million in Q4 2025, and -$5.7 million in Q3 2025.